TOBI Podhaler (tobramycin inhalation powder) 28mg capsules by Novartis Novartis' TOBI Podhaler, indicated for the management of cystic fibrosis in patients with Pseudomonas aeruginosa bacteria in the ...
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes ...
Novartis receives EU approval recommendation for TOBI® Podhaler®, a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients CHMP supports approval of TOBI Podhaler, a ...
Tobramycin 28mg; per cap; dry pwd for oral inhalation; with Podhaler device. <6yrs: not established. For oral inhalation use only with Podhaler device; do not swallow caps. Give in alternate 28-day ...
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US - TOBI Podhaler is indicated for certain cystic fibrosis (CF) ...
Novartis Pharmaceuticals Corporation has received the US Food and Drug Administration (FDA) approval for TOBI Podhaler (tobramycin inhalation powder) 28 mg per capsule for the management of cystic ...
Novartis AG 's ( NVS) TOBI Podhaler (tobramycin inhalation powder) recently received US Food and Drug Administration (FDA) approval for the treatment of bacterial lung infection in cystic fibrosis ...
Cystic fibrosis patients in England and Wales will now have access to two new drugs from Novartis and Forest Laboratories to treat lung infections. Both the Tobi Podhaler (tobramycin) from Novartis ...
Novartis’ Tobi Podhaler should be available to cystic fibrosis patients with a lung infection, according to the medicines cost-effectiveness body for England and Wales, but Forest’s Colobreathe’s was ...
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. TOBI PODHALER contains the active ingredient tobramycin. TOBI PODHALER ...
Novartis International AG / Novartis receives EU approval recommendation for TOBI® Podhaler®, a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients processed and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results